December 1, 2009 (FinancialWire) — Drugmaker Sanofi-aventis’ (NYSE: SNY) Sanofi-aventis U.S. unit said it has signed an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions in North America.

Under the terms of the agreement, sanofi-aventis U.S. will make an upfront payment and Intelliject will be eligible for future milestone payments and royalties on product sales.

Paris-based Sanofi-aventis is a global pharmaceutical company that discovers, develops and distributes therapeutic solutions.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.